Given that unrestricted WNT activation is a critical initiating event in CRC pathogenesis, most frequently via loss-of-function APC mutations45–47, it is natural that therapeutic discovery efforts and screening approaches have been directed towards disrupting this potent developmental pathway27,48–50. This evidence concerns the gene APC and colorectal carcinoma.